(Palomo T, Beninger RJ, Archer T, eds), pp 259 –288. Madrid:
Fundacion Cerebro y Mente.
Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL,
Ross CA (1998) Intranuclear neuronal inclusions in Huntington's
disease and dentatorubral and pallidoluysian atrophy: correlation
between the density of inclusions and IT15 CAG triplet repeat
length. Neurobiol Dis 4:387–397.
Beal MF, Ferrante RJ (2004) Experimental therapeutics in transgenic
mouse models of Huntington's disease. Nat Rev Neurosci
5:373–384.
Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi
A, Nairn AC, Messer A, Greengard P (2000) Severe deficiencies in
dopamine signalling in presymptomatic Huntington's disease mice.
Proc Natl Acad Sci USA 97:6809 – 6814.
Boutell JM, Thomas P, Neal JW, Weston VJ, Duce J, Harper PS,
Jones AL (1999) Aberrant interactions of transcriptional repressor
proteins with the Huntington's disease gene product, huntingtin.
Hum Mol Genet 8:1647–1655.
Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies
SW, Penney JB, Bates GP, Young AB (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of
an abnormal human huntington disease gene. Proc Natl Acad Sci
USA 95:6480 – 6485.
Chai Y, Wu L, Griffin JD, Paulson HL (2001) The role of protein
composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem 276:44889 – 44897.
Chai Y, Shao J, Miller VM, Williams A, Paulson HL (2002) Live-cell
imaging reveals divergent intracelluar dynamics of polyglutamine
disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci USA 99:9310 –9315.
Chan EYW, Luthi-Carter R, Strand A, Solano SM, Hanson SA, DeJohn
MM, Kooperberg C, Chase KO, DiFiglia M, Young AB, Leavitt BR,
Cha J-HJ, Aronin N, Hayden MR, Olson JM (2002) Increased
huntingtin protein length reduces the number of polyglutamineinduced gene expression changes in mouse models of Huntington's disease. Hum Mol Genet 11:1939 –1951.
Chevalier-Larsen ES, O'Brien CJ, Wang H, Jenkins SC, Holder L,
Lieberman AP, Merry DE (2004) Castration restores function and
neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci 24:4778 – 4786.
Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A,
Orr HT, Beaudet AL, Zoghbi HY (1999) Mutation of the E6-AP
ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron
24:879 – 892.
Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA,
Scherzinger E, Wanker EE, Mangiarini L, Bates GP (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell
90:537–548.
de la Monte SM, Vonsattel JP, Richardson EP (1988) Morphometric
demonstration of atrophic changes in the cerebral cortex, white
matter, and neostriatum in Huntington's disease. J Neuropathol
Exp Neurol 47:516 –525.
DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP,
Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear
inclusions and dystrophic neurites in brain. Science 277:
1990 –1993.
Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM,
Mouradian MM, Young AB, Tanese N, Krainc D (2002) Sp1 and
TAFII130 transcriptional activity disrupted in early Huntington's
disease. Science 296:2238 –2243.
Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K,
Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM (2003) Histone
deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease
mice. J Neurosci 23:9418 –9427.
